Moreover, honokiol and erlotinib exhibited combinatory anti-cancer effects in 1170 cells and EGFR mutant cell lines H1650 and H1975 as demonstrated by significant abrogation of phospho-Akt and phospho-ERK expression and an increase in PARP cleavage. The gene discussed is EGFR; the disease is cancer.